Treace Medical Concepts Reports 7% to 10% Revenue Growth in Q1 2025 Results

Reuters

2025/05/09

Treace Medical Concepts Reports 7% to 10% Revenue Growth in Q1 2025 Results

Treace Medical Concepts Inc. has reported its first-quarter 2025 financial results, highlighting a significant growth in revenue. The company achieved a revenue figure of $230 million, marking a 7% to 10% increase compared to the full-year 2024. This performance aligns with the company's expectations of achieving a breakeven Adjusted EBITDA for the full-year 2025. Treace Medical Concepts Inc. uses Adjusted EBITDA as a key financial metric, which excludes various expenses such as depreciation, amortization, interest, taxes, and other costs. This non-GAAP measure is employed to provide a clearer picture of the company's operating results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Treace Medical Concepts Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9447693-en) on May 08, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2534667491"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534667491\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2534667491?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-09 04:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534667491","market":"us","top_or_hot":-1,"title":"Treace Medical Concepts Reports 7% to 10% Revenue Growth in Q1 2025 Results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Treace Medical Concepts Reports 7% to 10% Revenue Growth in Q1 2025 Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Treace Medical Concepts Inc. has reported its first-quarter 2025 financial results, highlighting a significant growth in revenue. The company achieved a revenue figure of $230 million, marking a 7% to 10% increase compared to the full-year 2024. This performance aligns with the company's expectations of achieving a breakeven Adjusted EBITDA for the full-year 2025. Treace Medical Concepts Inc. uses Adjusted EBITDA as a key financial metric, which excludes various expenses such as depreciation, amortization, interest, taxes, and other costs. This non-GAAP measure is employed to provide a clearer picture of the company's operating results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Treace Medical Concepts Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9447693-en) on May 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Treace Medical Concepts Reports 7% to 10% Revenue Growth in Q1 2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTreace Medical Concepts Reports 7% to 10% Revenue Growth in Q1 2025 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-09 04:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Treace Medical Concepts Reports 7% to 10% Revenue Growth in Q1 2025 Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Treace Medical Concepts Inc. has reported its first-quarter 2025 financial results, highlighting a significant growth in revenue. The company achieved a revenue figure of $230 million, marking a 7% to 10% increase compared to the full-year 2024. This performance aligns with the company's expectations of achieving a breakeven Adjusted EBITDA for the full-year 2025. Treace Medical Concepts Inc. uses Adjusted EBITDA as a key financial metric, which excludes various expenses such as depreciation, amortization, interest, taxes, and other costs. This non-GAAP measure is employed to provide a clearer picture of the company's operating results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Treace Medical Concepts Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9447693-en) on May 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL5bTfjZ:1","article_id":"2534667491","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534667491","pubTimestamp":1746734903,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Treace Medical Concepts Inc. has reported its first-quarter 2025 financial results, highlighting a significant growth in revenue. The company achieved a revenue figure of $230 million, marking a 7% to 10% increase compared to the full-year 2024. This performance aligns with the company's expectations of achieving a breakeven Adjusted EBITDA for the full-year 2025. Treace Medical Concepts Inc. uses Adjusted EBITDA as a key financial metric, which excludes various expenses such as depreciation, amortization, interest, taxes, and other costs. This non-GAAP measure is employed to provide a clearer picture of the company's operating results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Treace Medical Concepts Inc. published the original c","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","TMCI":"Treace Medical Concepts, Inc."},"translate_title":"Treace Medical Concepts报告2025年第一季度收入增长7%至10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMCI":0.9,"NDAQ":0.9},"content_text":"Treace Medical Concepts Reports 7% to 10% Revenue Growth in Q1 2025 Results\n    \n\n        Treace Medical Concepts Inc. has reported its first-quarter 2025 financial results, highlighting a significant growth in revenue. The company achieved a revenue figure of $230 million, marking a 7% to 10% increase compared to the full-year 2024. This performance aligns with the company's expectations of achieving a breakeven Adjusted EBITDA for the full-year 2025. Treace Medical Concepts Inc. uses Adjusted EBITDA as a key financial metric, which excludes various expenses such as depreciation, amortization, interest, taxes, and other costs. This non-GAAP measure is employed to provide a clearer picture of the company's operating results.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Treace Medical Concepts Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9447693-en) on May 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}